Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 28, 2024 11:26am

63 Views

Post# 36060385

RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

" The TROPION-Lung01 trial has already raised other issues in the past, most notably an undetermined number of deaths attributed to interstitial lung disease that AstraZeneca and Daiichi discussed at last year’s European Society for Medical Oncology (ESMO) Congress.

In his same conversation with Fierce Biotech three months ago, Fredrickson accepted that the FDA will be taking these adverse events into account as part of its decision-making process, but he sounded confident in the solution the companies set out at that conference. "

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – July 3, 2024